Fate Therapeutics (FATE) Net Cash Flow (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Net Cash Flow came in at -$7.2 million in Q1 2026, down 181.62% YoY from $8.9 million in Q1 2025, and down 220.46% on a QoQ basis from $6.0 million in Q4 2025.
Fate Therapeutics (FATE) Net Cash Flow (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Net Cash Flow data on file, last reported at -$7.2 million in Q1 2026.
- Quarterly Net Cash Flow fell 181.62% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.5 million (up 93.21% YoY) and the FY2025 annual result came in at $10.6 million, up 198.22% from the prior year.
- Net Cash Flow fell to -$7.2 million in Q1 2026, from $6.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $79.5 million in Q1 2024 to a low of -$84.4 million in Q2 2024.
- A 5-year average of -$5.8 million and a median of -$3.7 million in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 511.39% in 2024, down 1883.71% in 2024.
- Tracing FATE's Net Cash Flow over 5 years: stood at -$20.8 million in 2022, then jumped by 141.12% to $8.5 million in 2023, then plunged by 121.71% to -$1.9 million in 2024, then jumped by 424.12% to $6.0 million in 2025, then slumped by 220.46% to -$7.2 million in 2026.
- The last three Net Cash Flow figures came in at -$7.2 million (Q1 2026), $6.0 million (Q4 2025), and -$627000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -7.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.24 Mn |
| Mar 31, 2026 | -7.24 Mn |
| Dec 31, 2025 | 6.01 Mn |
| Dec 31, 2025 | 6.01 Mn |
| Sep 30, 2025 | -627,000.00 |
| Sep 30, 2025 | -627,000.00 |
| Jun 30, 2025 | -3.67 Mn |
| Jun 30, 2025 | -3.67 Mn |
| Mar 31, 2025 | 8.86 Mn |
| Mar 31, 2025 | 8.86 Mn |
| Dec 31, 2024 | -1.85 Mn |
| Dec 31, 2024 | -1.85 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Jun 30, 2024 | -84.41 Mn |
| Jun 30, 2024 | -84.41 Mn |
| Mar 31, 2024 | 79.45 Mn |
| Mar 31, 2024 | 79.45 Mn |
| Dec 31, 2023 | 8.54 Mn |
| Dec 31, 2023 | 8.54 Mn |